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Abstract: Individuals over 65 years of age experience the new onset of seizures at a preva-
lence rate of roughly twice that of younger adults. Differences in physiology, need of con-
comitant medications, and liability for cognitive deficits in this population, make the choice of 
anticonvulsant drugs especially important. This paper reviews topiramate (TPM), a treatment 
for many types of seizures, with the above risks in mind. In particular, we discuss efficacy and 
pharmacokinetics with emphasis on the older patient, and adverse events in both the younger 
and older adult. With most studies of TPM-induced cognitive deficits having been performed in 
younger adults and volunteers, we discuss the implications for the older adult. Even in studies 
of younger individuals, up to 50% discontinue TPM because of intolerable cognitive deficits. 
Most studies find specific declines in working memory and verbal fluency. In conclusion, we 
give recommendations for use of this antiepileptic drug in this population.
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Introduction
The literature on idiopathic symptomatic seizure disorders has consistently shown that 
the incidence increases with age, such that by the seventh decade, the risk doubles, 
and by the eighth, triples.1,2 Two separate population-based studies now have shown 
that at least 25% of patients with newly diagnosed unprovoked seizures are over 
60 years old.3–5
The underlying etiologies may include cerebrovascular disease and stroke, 
occurring in up to half of cases.5–7 Interestingly, ictal activity may be found in small 
vessel disease, commonly seen on imaging in older individuals.8 After an obvious 
vascular event such as an acute, subarachnoid hemorrhage, a seizure may occur within 
hours. If seizures do occur in association with vascular disease, they are more likely 
to recur if dementia or another neurological disease co-exists.7 In evaluating the most 
common etiologies for unprovoked seizures, one prospective population-based study 
has found that the most common etiologies were stroke, followed by brain tumor, and 
Alzheimer’s disease.3 If stroke had been the etiology, the location was important, with 
cortical involvement being more likely to produce seizure activity than sub-cortical 
location of the stroke.8
The clinical features of epilepsy in elderly patients often are quite different 
from those of younger patients, with studies showing that most often, older patients 
experience simple partial or complex partial seizures.7,9 Although the estimated annual 
incidence is as high as 134 per 100,000 in older individuals, some authors believe 
this to be a conservative number, with misdiagnosis and un-diagnosis common. Clinical Interventions in Aging 2010:5 90
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Older patients often present with altered mental status, 
confusion, memory lapse, or syncope,2 making the seizure 
disorder go unrecognized. It has been shown that in older 
patients with a new diagnosis of epilepsy, the primary care 
physician or internist had made the correct diagnosis only 
73.3% of the time. Other diagnoses may include altered 
mental status (41.8%), confusion, (37.5%), blackout spells 
(29.3%), and memory disturbance (17.2%) – the numbers 
do not add up because patients may have more than one 
diagnosis made.10 The most common type of seizure in the 
older adult is partial onset, occurring in 68%, with 10% to 
30% presenting as tonic–clonic status epilepticus.7
Older individuals, relatively frail due to their susceptibility 
to both cerebrovascular disease and to new onset seizure 
disorder, require that safe medications for seizure control be 
utilized to treat their disorders. The ideal medication for sei-
zure control would have no drug–drug interactions, especially 
with antihypertensive drugs, limited sedation, low risk of gait 
disturbance, no effect on appetite, no associated metabolic 
disturbance, and no alteration of cognition. There are no 
medications presently available to fit this profile. However, 
compared to other anticonvulsants, the side effect profile of 
topiramate (TPM) may offer some patients an alternative 
under certain circumstances.
In this paper, we plan to discuss the use of TPM in older 
patients with both generalized and partial seizures. The focus 
in this paper is on efficacy studies, pharmacokinetics, drug 
interactions and side effects in the older population, especially 
as they apply to individuals with concurrent cognitive 
impairment due to medical co-morbidity. How TPM would 
compare to an ideal AED for use in the elderly is discussed.
Mechanism of TPM
The anticonvulsant activities of TPM differ from those of 
other anti-epileptic drugs (AEDs) such as phenytoin (PHT) 
and carbamazepine (CBZ). It does exhibit the property 
of state and voltage dependent blockade of neuronal Na+ 
channels, as do the others, but in addition, TPM influences the 
activity of Ca2+, GABAA receptors, and AMPA (α-amino-3-
hydroxy-5-methylisoxazole-4-propionic acid)/kainate glutamate 
receptors.11 TPM also has the unusual quality of inhibiting 
some isozymes of carbonic anhydrase.12 The ophthalmologic 
implications will be discussed in a separate section.13
Efficacy studies of TPM  
in the elderly
TPM has been reported to show effectiveness in most seizure 
types except perhaps for absence.9 Studies have found it 
  useful for intractable epilepsy.14 However, few studies have 
been performed specifically on individuals over 65.
Most efficacy studies of TPM as an AED have involved 
the population younger than 67 years old.14–23 Many efficacy 
studies of older individuals have included them only as part 
of general adult studies.24–26 Table 1 lists trials of TPM that 
have incorporated older patients.
For example, Gilliam and colleagues evaluated 24 
individuals over 65 as part of an efficacy study of partial 
complex seizures; a total of 252 patients were evaluated.25 
Arroyo assessed 10 patients over age 65 as part of a general 
study evaluating a total of 470 patients.26 An open label 
study by Stefan and colleagues exclusively evaluated an 
older cohort of 107 patients (mean age of 69 years) with 
TPM mono-therapy, for a one-year period.27 48% of patients 
began TPM as monotherapy, (mean dose of TPM was 
98 ± 50 mg/day) with the percentage increasing to 65% at 
endpoint. The mean TPM dose for those in combination 
therapy was 153 ± 87 mg/day. Mean monthly seizure 
frequency overall decreased from 3.7 ± 15 to 1.6 ± 7.7, with 
78% of patients showing at least 50% seizure reduction, and 
44% being seizure free for the one year period.
In summary, data shows lower doses of TPM, when used 
as monotherapy for the treatment of epilepsy in the older 
patient, may be effective, with 50 to 75 mg, sufficient for 
seizure control.28
Pharmacokinetics
Absorption
TPM is rapidly and almost completely absorbed by the gut, 
reaching peak plasma concentrations between 2 and 4 hours 
after ingestion,29,30 and bioavailability after oral administration 
is almost entirely unchanged, between 81% and 95%.31 
Factors that may slow the absorption include high fat foods 
and concomitant medications, such as valproate, carbam-
azepine, and phenytoin, which produce changes consistent 
with the metabolic changes resulting from cytochrome P450 
enzyme induction.32,33
Distribution and protein binding
While plasma albumin levels decline with age, alpha 1 
glycoprotein either remains unchanged or may increase. 
Albumin and alpha-1 acid glycoprotein (AAG) are responsible 
for most plasma drug binding. Albumin preferentially binds 
acidic drugs and AAG primarily binds alkaline or neutral drugs. 
Competition for protein binding may result in fewer available 
binding sites for albumin, and transient increases in free drug 
concentrations may occur, influencing the concentration and Clinical Interventions in Aging 2010:5 91
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clearance of concomitantly administered medications.34,35 TPM 
binds to AAG, globulins, lipoproteins, and erythrocytes, only 
binding to plasma proteins to a small degree (13%–17%).36,37 
As a result of these binding and distribution properties, TPM 
free (unbound) serum concentrations may not be as affected 
as other medications by age-related reductions of plasma 
albumin levels, or by significant protein binding displacement 
interactions when used in combination with lipophilic and 
protein-bound AEDs.38
Metabolism
Around 70% of TPM is excreted without metabolism, unchanged 
in the urine, unless in the presence of other medications which 
are potent enzyme inducers.37,39 The six known metabolites of 
TPM themselves show little to no pharmacological activity.37 
While TPM alone does not appear to either inhibit or induce 
drug metabolizing enzymes at clinical doses, it does inhibit 
CYP2C19 at plasma concentrations doses equivalent to 
5% to 15% times higher than recommended.33 Regression 
analysis has found that when combined with PHT, CBZ, 
phenobarbital, and oxcarbazepine, TPM concentrations were 
significantly lower, compared with TPM concentrations during 
monotherapy.40 TPM alone has a half-life of around 24 hours, 
decreasing by about 50% in the presence of enzyme inducing 
medications. This results in a rise of metabolized TPM by 
50% to 70%.39 Neither valproate (VPA) nor lamotrigine (LTG) 
have a significant influence on TPM metabolism.39
Most AEDs are eliminated primarily by the clearance 
of unbound drug. Aging is associated with an increase in 
unbound drug, associated with a decrease in clearance. 
Without a commensurate decrease in protein binding, serum 
concentrations of a drug would be expected to rise. One 
single-dose study of 16 volunteers between ages 65 to 85 
confirmed this by finding that TPM clearance was reduced 
by about 20% when compared to 16 younger adult controls.41 
This study, however, seems to be at odds with another finding 
that while small increases in serum TPM concentrations 
have been recorded in patients with impairment in hepatic 
function, age-related changes in hepatic function alone do 
not appear to result in significant clinical impact or the need 
for adjustments in TPM dosing.27
As monotherapy, TPM has a half-life of around 24 hours, 
decreasing by about 50% in the presence of enzyme inducers, 
making the amount of metabolized TPM rise by 50%–70%.39
Renal excretion
TPM is primarily excreted unchanged by the kidneys, and is 
not extensively metabolized by the liver.42 Aging may decrease 
tubular excretory capacity and glomerular filtration rate by 
25% to 50% by age 90.43 While renal elimination of most drugs 
Table 1 Studies assessing the effects of TPM on epilepsy in older patients. The number is far fewer than in younger adults, and most 
often older subjects are included only as part of studies involving younger adults
Author Seizure type Number of  
subjects
Min dose Max dose % SF at end of study
Older adults Total (mg) (mg)
Gilliam25 Partial epilepsy 24 (65) 252 50, or 25  
if 50 kg
500, or 200 if  
50 kg
54% on 500 mg, 
39% on 200 mg
Priviteraa,24 Newly dx epilepsy 37 409 100 200 49%
Arroyo26 Epilepsy 10 470 50 400 After 12 mos:  
76% on 400 mg,  
59% on 50 mg
Groselj89 Epilepsy 60 (60) 100 400 64% SF  
87% 50%
Guerrini90 Focal and generalized  
epilepsy
Mean age 69.2 (1–88 years 
old), ages not further  
described
25 500 44.3% SF,  
76.3% 50%
Runge91 Newly or recently  
dx epilepsy
145 (65) 50 100 40.7%, mean  
duration 185 days
Stefan27 Elderly, epilepsy 107 (mean age 69) 98 (monotx) 153  
(adjunctive tx)
78% 50%
Ramsay92 Elderly, partial-onset  
seizures
77 (60) 50 (N = 38) 200 (N = 39) 52% on 50 mg,  
58% on 200 mg
aStudy compared TPM with CBZ and VPA.
Abbreviations: dx, diagnosis; SF, seizure free; tx, therapy; TPM, topiramate; CBZ, carbamazepine; VPA, valproate.Clinical Interventions in Aging 2010:5 92
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is a measure of endogenous creatinine clearance, renal function 
and creatinine clearance are not always reliable measures in 
the elderly. Reduced muscle mass with ensuing decreased 
muscle breakdown results in a reduced entry of creatinine into 
the circulation. A normal serum creatinine, particularly in an 
older woman, may reflect incipient renal failure.43
One study compared a group of 65–85-year-olds with 
compromised renal function to younger adults, after a single 
oral 100 mg dose of TPM. The TPM clearance was reduced 
in the elderly, with the half-life 13% longer than in the 
younger subjects. There also was a 23% higher maximum 
plasma concentration.41 Therefore, it is generally felt that the 
recommended dose of TPM, particularly in the older patient, 
whose clearance may decrease by up to 50%, should be lower 
even in the face of a normal serum creatinine.44
Adverse drug reactions
An adverse drug reaction (ADR) is defined as “an appreciably 
harmful or unpleasant reaction, resulting from an intervention 
related to the use of a medicinal product, which predicts 
hazard from future administration and warrants prevention 
or specific treatment, or alteration of the dosage regimen, or 
withdrawal of the product”.45
The study in the above section by Stefan27 found that 
during the TPM trial, 67% of the 75 patients that had been 
taking AEDs pre-trial, reported adverse events (AEs), and 
of those, 43% of the ADRs were considered likely due 
to the medication. In 5% of patients, convulsions leading 
to hospitalization were reported. Other ADRs included: 
dizziness, fatigue, headache, cognitive disturbance, 
depression, paresthesia, and nausea. In this study, 12% of 
the patients reported cognitive disturbance; 11% described 
memory impairment, and 2 subjects had additional language 
impairment. Two subjects reported additional difficulties 
with praxis and psychomotor slowing. In all, however, TPM 
was considered well tolerated, with good efficacy. While 
there were cognitive complaints in a significant minority of 
patients, they seemed to be tolerable in most cases.27
In a study of the young adult population, ADRs in gen-
eral were markedly attenuated by slowly titrating the dose. 
A multi-center study of 213 patients aged 16 to 65 (mean age 
30.1 ± 10.2), with intractable epilepsy (defined as 2 seizures 
in a 4 week period), found that by beginning TPM at 25 mg 
increasing by 25 mg per week, doses of 300 mg per day could 
be reached, and both efficacy and AEs were comparable to the 
authors’ previous trial using 600 mg. During the study, 22% 
developed ADRs entering the titration phase, 81% during the 
titration phase, and 45% during the maintenance phase of 
the study. The most common AE was dizziness (10%). Other 
ADRs were somnolence (3.3%), anorexia (2.3%), and weight 
loss (2.3%), with other ADRs reported at less than 2%. The 
mean weight loss was 1.1 ± 1.3 kg.46 An earlier study had 
examined the incidence of all ADRs in patients who had taken 
TPM prior to that date, assessing studies until 1996. While 
the ages of the patients were not given, the authors found that 
of the 1809 individuals originally exposed to TPM for the 
treatment of partial seizures, the percentage of subjects with 
confusion, abnormal thinking or impaired concentration were 
as follows: 8% on placebo, 40% on 200 mg, 36% on 400 mg 
59% on 600 mg, 58% on 800 mg and 75% on 1000 mg. ADRs 
were considered mild to moderate in this population, whose 
age was not defined.47
One post marketing study of a mostly young adult 
population, (ages 18–60, with 3% of the 701 patients older 
than 60) treated mostly for complex partial seizures, found 
that even this young cohort suffered from significant cognitive 
changes. In this open, observational study, only 2.4% of the 
patients were taking TPM as monotherapy, suggesting that 
the ADRs were possibly a result of not only combination 
therapy, but of the concomitant neuropsychiatric diagnoses 
that the authors mention that were also present in the popula-
tion studied. Psychomotor slowing was found in 47.8% of 
patients, cognitive ADRs not otherwise specified in 39.1%, 
and behavioral changes were found in 3 patients (18%). In 
subjects without co-morbid psychiatric diagnoses, psycho-
motor slowing occurred in only 29.9% of patients. No seizure 
type put patients at increased risk for discontinuing TPM; 
CBZ seemed to be the concomitant medication most often 
associated with discontinuation. Psychomotor slowing was 
the most consistent AE after 6 months.48
Another study of mostly young adults (mean age 
32 ± 16.8 years old, oldest subject 75) found levetiracetam had a 
higher retention rate for patients than TPM; the most important 
reason given for discontinuation of TPM was cognitive side 
effects.49 The efficacy of the two medications was comparable. 
The specific cognitive effects of TPM in both volunteers and 
patients with epilepsy are discussed further below.
Metabolic acidosis, nephrolithiasis, 
and osteopenia
As a carbonic anhydrase inhibitor, TPM reduces the 
excretion of urinary citrate, resulting in a rise in urinary 
pH. TPM has been found to inhibit the activity of specific 
carbonic anhydrase enzymes in the kidney, contributing 
to the development of metabolic acidosis, hypocitratu-
ria, hypercalciuria and elevated urinary pH–all of which Clinical Interventions in Aging 2010:5 93
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may lead to an increased risk of nephrolithiasis.50,51 Other 
contributors to these calcium phosphate kidney stones include 
TPM-induced systemic metabolic acidosis and lower urinary 
citrate excretion.51 The hyperchloremic, non-anion gap 
metabolic acidosis may begin as early as 1 week after beginning 
TPM treatment or within 1 week of a dose increase. The cal-
culi may develop in approximately 1.5% of patients on TPM, 
2 to 4 times the incidence expected in the general population.52 
The risk of nephrolithiasis is increased by pre-existing renal 
disease, respiratory disorders, diarrhea, status epilepticus and 
treatment with other carbonic anhydrase inhibitors, such as 
acetazolamide. To aid in its prevention, ample hydration is 
important when prescribing TPM. Metabolic acidosis may 
result in cardiac arrhythmia, osteomalacia, and osteoporosis, 
with an increase in risk of spontaneous bone fracture. While the 
clinician may prescribe alkaline products, the discontinuation 
or tapering of TPM may need to be considered. Monitoring of 
serum electrolytes every 6 months should be considered.52
Weight loss
Appetite suppression and weight loss have been documented 
in patients treated with TPM for both epilepsy and psychiatric 
disorders. In a recent 1-year, open-label, flexible-dose clinical 
trial of 107 elderly patients (mean age 69 years) on TPM, 
4.7% noted a decreased appetite and 3.7% were found to 
have frank weight loss. Nausea was reported in 5.6 % of the 
sample, leading to discontinuation of TPM in 1.9% of the 
study population. Body weight decreased by 1.8 ± 4.6 kg 
from baseline to the follow-up visit six (6 months later), and 
decreased 1.9 ± 5.0 kg from baseline to the visit 52 weeks later. 
Although desirable in overweight or obese patients, this effect 
may be unwanted in frail elderly or underweight patients.27
Paresthesias
In an analysis of tolerability of TPM for migraine prevention, 
paresthesias were found to be the most common among 
all ADRs: 35% of patients (N = 2350 taking 50 mg/day 
complained of paresthesias, 51% on TPM 100 mg/day 
(N = 386), 49% (N = 514) taking TPM of 200 mg/day, and 
only 6% (N = 445) on placebo. 8% of 386 subjects withdrew 
from the because of this complaint.53
Secondary angle closure glaucoma 
and decreased vision
While rare, TPM has been associated with the unusual 
AE of acute, secondary angle closure glaucoma. This 
ophthalmologic emergency, usually treated with the carbonic 
anhydrase inhibitor acetazolamide, cannot successfully be 
treated in this standard manner in the presence of TPM, also 
with these properties.12 The sudden onset of decreased visual 
acuity accompanied by hyperemia and ocular pain has been 
reported, usually within the first month of treatment with 
TPM. This sudden adverse effect has been aborted with 
discontinuation of TPM.54–56
A case of a patient with sudden decreased vision while on 
TPM also has been described. Ophthalmologic exam showed 
findings consistent with maculopathy, but the patient’s vision 
did not improve even after TPM had been discontinued for 
six months.13
Psychiatric adverse events and TPM 
in the older adult
Patients with epilepsy are reported to have 5 times the suicide 
rate as the general population, and patients with temporal lobe 
epilepsy (TLE) and complex partial seizures in particular 
have around a 25-fold increase in rate. The psychological 
distress of seizure disorders, along with disturbances in 
serotonin metabolism contributing to the pathogenesis of 
suicidal behavior, may both be factors underlying these 
statistics.57 The mechanism of action of a particular AED 
prescribed is therefore critical, and recently, a number of 
AEDs have been associated with an increase in suicide risk 
in patients with both psychiatric and seizure disorders.57,58
In 2008, the US Food and Drug Administration (FDA) 
posted an advisory to healthcare professionals regarding 
suicidality associated with AEDs, stating that as a class, 
there is a possible risk between 11 such drugs, including 
TPM, and suicidal ideation, within 1 week of beginning 
treatment. This seems to occur to the same extent in both 
epilepsy and psychiatric patients. The FDA states that the 
risk is roughly twice that of placebo-treated patients (0.43% 
versus 0.22%).59
Despite at least one significant study showing a positive 
effect on anger and depression in a young adult depressed 
population,60 TPM has no effect on serotonin function, and 
would not be expected to exert an antidepressant effect 
on patients. In fact, overall, TPM-treated patients have a 
prevalence of suicidal ideation, attempts, and completed 
suicide of 0.5%, compared with 0.15% of placebo recipients, 
in randomized, double-blind clinical trials.36 One author has 
recommended that until more studies have been completed, 
TPM not be used in patients with either TLE or hippocampal 
sclerosis, to prevent the onset of suicidal behavior.57
Other psychiatric adverse effects have been associated 
with TPM, and patients at increased risk may be those with 
the following characteristics: low seizure frequency prior to Clinical Interventions in Aging 2010:5 94
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initiation of therapy, family and personal history of psychiatric 
disorder or epilepsy, personal history of febrile convulsions, 
presence of tonic/clonic seizures, and high starting dose or 
rapid titration of the medication.61 Specific reported psychiatric 
symptoms have included nervousness, depression, anorexia, 
agitation, and mood disruption.57 Psychiatric adverse effects 
have been seen as dose related, and one author has recommended 
initiating treatment in low doses, 15 to 25 mg/day, with gradual 
titration to avoid these effects.37
In one observational follow-up study of 431 patients 
treated with TPM, psychiatric adverse events occurred in 
103 (23.9%) subjects. Specific events included 46 (10.7%) 
with affective disorder, 16 (3.7%) with psychotic disorder, 
and 24 (5.6%) with aggressive behavior with or without 
irritability. Agitation, anxiety, and hostility were found in 
17 (3.9%). It was noted that the titration schedule of TPM 
appeared to be correlated with the onset of these psychiatric 
symptoms.61 Mood instability, correlating with dose of TPM, 
has also been documented in 17% of patients in placebo-
controlled studies,58 along with psychotic symptoms, which 
resolved upon discontinuation of TPM.62
Concomitant medications and risk 
for delirium in the elderly
Delirium, with its connotation of a grave prognosis, is often 
under-recognized in emergency departments.63 AEs due to 
TPM, however, do not appear to play a major role in its 
etiology. In a study of elderly patients with delirium, only 
6% were found to be taking anticonvulsant medications.64 
Common medication-induced causes of delirium include 
anticholinergic drugs65 and polypharmacy, as noted in a 
recent study finding that older patients with dementia and 
delirium had been taking more than 8 medications per day.64 
Other medications frequently found to cause delirium include 
opiates, corticosteroids, and benzodiazepines.66
Cognitive impairment in older 
patients with epilepsy
Patients with epilepsy may suffer from cognitive impairment, 
multi-factorial in nature, independent of AEDs. Moreover, 
epilepsy may cause individuals to suffer from poorer education 
and fewer social supports than the general population, factors 
that have been seen in observational studies to be associated 
with an increased risk for cognitive decline in later years.67–70
Seizure disorders of differing etiologies have differing 
effects on cognition. For example, seizures that occur in 
conjunction with small strokes, depending on location, may 
have no demonstrable cognitive sequelae. But a seizure 
disorder resulting from a frontal lobe or limbic lesion may 
produce memory or language changes.67 Idiopathic epilepsies 
are apparently less likely to be associated with cognitive 
impairment than seizure disorders secondary to localized 
lesions.67 TLE often is associated with deficits in language, 
verbal and visual skills, as discussed in studies below. Table 2 
shows some of the studies assessing changes in cognition that 
have been performed on patients, both younger and older, 
with epilepsy.
But several studies attempting to assess cognition in 
patients with epilepsy have had methodological difficulties. 
One cross-sectional study evaluated 209 consecutive 
patients with TLE, monitoring the frequency of seizures per 
month, age of the patients at the onset of seizures, education, 
type of seizures, frequency of interictal epileptiform 
discharges, and AED taken. Factoring out these variables, 
the authors found that subjects with a longer duration of 
refractory TLE were the most impaired. The conclusion 
was that refractory TLE is associated with slow, ongoing 
cognitive decline.71 This correlational study, however, does 
not connote risk.
TPM effects on cognition
Many studies have compared the cognitive effects of TPM 
versus other AEDs in patients with partial epilepsy. These 
outcome studies have examined mostly young adults, with only 
a few studies exclusively involving the elderly. While the studies 
often have used differing neuropsychological batteries, when 
taken as a whole, the conclusions are similar – that there is such 
a marked effect on cognition that patients ask for discontinuation 
up to 47% to 50% of the time.72–74 Most of the studies have found 
deficits in working memory, and verbal fluency.74–77
One gross effect of TPM on daily life has been evaluated 
by examining motor vehicle performance and at least 
two studies have found TPM-related decreases in driving 
ability.72,78 In one, a subsample of patients with partial 
seizures taking part in a randomized, double-blind,  con-
trolled study comparing the cognitive effects of TPM and 
LTG, was administered a computerized task measuring 
scanning, divided attention, and effective field of view (via 
the Performance On-Line, or POL).72 The POL is thought 
to be an index for driving ability. Patients with a mean 
age of 40.2 (19–68), ¾ of whom were under 50 years old, 
were administered mean doses of either TPM 298.0 (SD 
8.6) mg or LTG 491.4 (SD 43.8) mg as adjuvant therapies 
to either PHT or CBZ for treatment of partial seizures. The 
TPM treated group suffered from restricted field of view 
after eight weeks, unable to overcome the deficits over the Clinical Interventions in Aging 2010:5 95
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16 weeks of the study. This was not thought to be due to 
angle closure glaucoma, a rare adverse event of the medica-
tion. There were also deficits in simple target identification 
and divided attention performance, in comparison with the 
LTG treated group. This effect was similar to the effects 
of a low dose of alcohol (0.045 mg/dL) or a low dose of 
alprazolam (0.5 mg).
Another study evaluating deaths in Washington State in 
which TPM had been detected in the serum by the medical 
examiner, discussed 3 cases in which TPM was thought to 
play a significant role, and several others in which it may 
have played a minor role.78
One interesting study evaluated cognitive function in 
patients with intractable partial seizures after discontinuation 
of TPM, finding that compared to controls undergoing 
discontinuation of another AED, all as a part of their 
presurgical preparation, there was a dramatic amelioration 
five of six measures of frontal lobe function (save for digits 
forward, improvements were seen in verbal fluency, digit 
span, trailmaking parts A and B, and block tapping). These 
tests demonstrate improvement in verbal fluency and working 
memory.79 The same author then retrospectively studied TPM 
versus LTG treated inpatients with pharmacoresistance, 
finding that the TPM treated patients scored more poorly 
on 20 of 23 neuropsychological tests. Specifically, not 
only were there significant decreases in verbal fluency and 
working memory, but also spatial processing, and tasks which 
require mental manipulation of material presented to the 
subject. The domains of cognition that were spared included 
visual processing speed and episodic verbal and nonverbal 
memory.76
In addressing whether low dose TPM affects cognition 
as adversely as does a higher dose, Lee et al compared the 
effects of 50, 75, and 100 mg on the cognition of 47 epilepsy 
patients, of a mean age of 31.4 (15–63). Sixteen patients 
(44%) complained of intellectual difficulties after 1 year, 
and these dose-related deficits were noted in domains of 
short-term memory and word retrieval, even on the lowest 
dose.77
There may be one circumstance in which TPM is 
actually preferable to LTG. Werz et al found that 70% 
of normal volunteers taking either TPM or LTG after a 
12-week trial, each at a maximum dose of 300 mg/day, 
again preferred LTG, having performed better on 19 of 23 
cognitive tests including (attention, memory, language, 
and cognitive and motor speed). Interestingly, 16% of 
patients preferred TPM, and 14% had no preference, not 
correlating with cognition or change in weight, but rather 
correlating with the mood state exam score (Profile of 
Mood States).80 While TPM is generally not used as a first 
line medication in the treatment of psychiatric disorders, 
there are occasional reports of its benefits in the treatment 
Table 2 Effects of epilepsy on cognition in young adults and the elderly
Study N Age at testing Epilepsy type Cognitive tests Results
Jokeit71 209 Mean  
25.4–43.8
TLE Full scale IQ 
(est from subtests:  
information,  
comprehension, similarities,  
digit symbol, picture  
completion block design)
Pts with 30 years of TLE  
did worse than pts with  
15–30 years of TLE  
Variables were controlled 
(age of onset, education  
  polypharmacy)
Martin93 52 64.6 ± 3.9 Chronic  
partial-intractable
Mattis Dementia Rating Scale 
(subtests: attention,  
initiation, construction,  
conceptualization memory,  
logical memory, 
immed and delayed recall, 
word fluency)
Impairments in all domains.   
Those taking AED  
poly-therapy N = 11 did  
worse than those on  
monotherapy attn,  
initiation and memory,  
and logical memory and 
delayed recall
Griffith94 78 (26 with  
epilepsy, 26 with  
MCI; 26 controls)
64.7 ± 3.8  
in the epilepsy group
Partial  
complex epilepsy
Weschler Memory Scale III  
subtests: 
Logical memory,  
CFL Word fluency test 
attention, memory  
construction, initiation  
conceptualization,  
phonemic word fluency
Patients with epilepsy on  
AED poly-therapy had the  
most cognitive deficits.  
Those on monotherapy  
were similar to the MCI  
patients not on  
  cholinesterase inhibitors
Abbreviations: AED, anti-epileptic drugs; attn, attention; est, estimate; immed, immediate; MCI, mild cognitive impairment; pts, patients; TLE, temporal lobe epilepsy.Clinical Interventions in Aging 2010:5 96
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of the irritability associated with depression and some 
bipolar disorders.81
The above section notes that partial complex seizures 
present most often in older patients and often cause cognitive 
impairment. Furthermore, the older adult population in general 
is more vulnerable to intellectual slowing, memory, tracking, 
and concept formation than the younger adult patient, on whom 
most studies of cognition have been done. The fact that older 
individuals in general have a diminished cognitive reserve 
when compared with younger adults, and often take many 
medications, making them more delirium-prone leads to the 
speculation that TPM may be even less well-tolerated by this 
population. It is striking that assessments of TPM on cognition 
have included so few older adults, as Table 3 demonstrates.
The recommendations of the authors of these studies 
was to begin TPM slowly, maintain the patient at the lowest 
possible dose, below 200 mg if possible, and to monitor the 
patient for amelioration of cognition over several months. 
In most of these studies, the overwhelming complaint was 
somnolence, causing even more distress than the cognitive 
slowing. This may have contributed to the inability to perform 
some of the required testing.
Conclusions
In comparing TPM to other available AEDs, two questions 
arise: 1. How does this medication fare in terms of primary 
and adverse effects compared with the others, and 2. Is there 
available data on adverse events specifically in older adults.
TPM is an effective AED, which also has analgesic prop-
erties for migraine headache, not discussed in this article. 
In patients without dementia, and with obesity, it may have 
unique value, when compared with other AEDs that may cause 
weight gain. These virtues must be weighed against a body 
of evidence from the young adult literature on the cognitive 
adverse events. While somnolence may have played some 
minor role in test performance, most studies have found frank 
deficits in word and name recognition, memory, concentration, 
and speed.82 These were subjectively noted by both patients and 
volunteers, and were a significant reason for withdrawal from 
studies. When compared with other AEDs such as LTG, leve-
tiracetam, and oxcarbazepine, the findings were significant.
Few studies have investigated the effects of TPM in older 
patients in particular, by evaluating cognition, balance, som-
nolence, electrolyte balance, or weight loss. One recent review 
has found that among AEDs, the “worst offenders” included 
primidone, phenobarbital, and PHT.83 Although TPM has not 
been evaluated in this population for these adverse effects, 
older patients are particularly susceptible to both cognitive 
impairment and risk of falling. This suggests that TPM, even 
in modest doses would very rarely be a first line AED.
The polypharmacy often prescribed to older adults, raises 
the risk of changes in TPM serum concentration. For example, 
clearance may be reduced by the following medications: 
amitriptyline, propranolol, lithium, and sumatriptan, all of 
which may increase the TPM level. VPA may lower the TPM 
level by 10% to 15%. These facts have raised the question of 
the need for assessment of serum concentrations, to ensure 
not only medication adherence in this population, but to 
monitor serum fluctuations. The reported effective blood 
levels are from 5 to 20 mg/L, but lower levels have been 
advocated to improve cognitive effects.84
TPM has many advantages, including posing no risk of 
  hyponatremia – as does CBZ and oxcarbazepine – and the addi-
tional therapeutic values mentioned above. However, in the case 
of the older patient, preferable AEDs may include CBZ, GBP, 
LTG, and levetiracetam.85,86 TPM is not generally recommended 
as a first line treatment for epilepsy in the older patient,85 but when 
it is being considered, for the cognitively intact older individual, it 
is recommended that the dose begin at around 25 mg, increasing 
no more rapidly than by 25 mg per week. The best results will 
be achieved by prescribing a total daily dose that results in low 
to moderate, rather than high serum levels.84,87,88
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